Evidence map›Paper›PMID 36780157›Full record

ArticleJAMA network open2023

Incidence, Risk, and Severity of SARS-CoV-2 Reinfections in Children and Adolescents Between March 2020 and July 2022 in Serbia.

Snežana Medic, Cleo Anastassopoulou, Zagorka Lozanov-Crvenkovic, Nataša Dragnic, Vladimir Petrovic, Mioljub Ristic, Tatjana Pustahija, Athanasios Tsakris, John P A Ioannidis

Open access · goldAbstract read
In one paragraph

Article in JAMA network open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Changing patterns of infectious diseases in children during the COVID-19 pandemic.Frontiers in cellular and infection microbiology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Snežana MedicDepartment of Epidemiology, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
Cleo AnastassopoulouDepartment of Microbiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Zagorka Lozanov-CrvenkovicDepartment of Mathematics and Informatics, Faculty of Science, University of Novi Sad, Novi Sad, Serbia.
Nataša DragnicDepartment of Social Medicine and Health Statistics With Informatics, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
Vladimir PetrovicDepartment of Epidemiology, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
Mioljub RisticDepartment of Epidemiology, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
Tatjana PustahijaDepartment of Epidemiology, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
Athanasios TsakrisDepartment of Microbiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
John P A IoannidisDepartment of Medicine, Stanford University, Stanford, California.
University of Novi Sad · RSInstitute of Public Health of Vojvodina · RSNational and Kapodistrian University of Athens · GRStanford University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: During the COVID-19 pandemic, children and adolescents were massively infected worldwide. In 2022, reinfections became a main feature of the endemic phase of SARS-CoV-2, so it is important to understand the epidemiology and clinical impact of reinfections. Objective: To assess the incidence, risk, and severity of pediatric SARS-CoV-2 reinfection. Design, Setting, and Participants: This retrospective cohort study used epidemiologic data of documented SARS-CoV-2 infections from the surveillance database of the Institute for Public Health of Vojvodina. A total of 32 524 children and adolescents from Vojvodina, Serbia, with laboratory-confirmed SARS-CoV-2 infection between March 6, 2020, and April 30, 2022, were followed up for reinfection until July 31, 2022. Main Outcomes and Measures: Incidence rates of documented SARS-CoV-2 reinfection per 1000 person-months, estimated risk of documented reinfection 90 days or more after laboratory confirmation of primary infection, reinfection severity, hospitalizations, and deaths. Results: The study cohort included 32 524 children and adolescents with COVID-19 (mean [SD] age, 11.2 [4.9] years; 15 953 [49.1%] male), including 964 children (3.0%) who experienced documented reinfection. The incidence rate of documented reinfections was 3.2 (95% CI, 3.0-3.4) cases per 1000 person-months and was highest in adolescents aged 12 to 17 years (3.4; 95% CI, 3.2-3.7). Most reinfections (905 [93.9%]) were recorded in 2022. The cumulative reinfection risk was 1.3% at 6 months, 1.9% at 9 months, 4.0% at 12 months, 6.7% at 15 months, 7.2% at 18 months, and 7.9% after 21 months. Pediatric COVID-19 cases were generally mild. The proportion of severe clinical forms decreased from 14 (1.4%) in initial episodes to 3 (0.3%) in reinfections. Reinfected children were approximately 5 times less likely to have severe disease during reinfection compared with initial infection (McNemar odds ratio, 0.2; 95% CI, 0.0-0.8). Pediatric reinfections rarely led to hospitalization (0.5% vs 1.3% during primary infections), and none resulted in death. Conclusions and Relevance: This cohort study found that the SARS-CoV-2 reinfection risk remained substantially lower for children and adolescents compared with adults as of July 2022. Pediatric infections were mild, and reinfections were even milder than primary infections.

Indexed as

COVID-19SARS-CoV-2AdolescentAdultChildCohort StudiesFemaleHumansIncidenceMalePandemicsReinfectionRetrospective StudiesSerbia

Identifiers

PMID36780157
PMCPMC9926322
OpenAlexW4320486390

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.